Bladder Cancer Clinical Trials

• Age ≥ 18 years

• Have relapsed/refractory HER2-altered malignancy; for selected cohorts, prospective confirmation of HER2 alteration by central testing is required

• Have progression of disease after the last systemic therapy, or be intolerant of last systemic therapy

• Have radiographically measurable disease by RECIST v1.1 and/or RANO-BM

• Eastern Cooperative Oncology Group (ECOG) performance score 0-1

• Have adequate baseline hematologic, liver and renal function

• Have left ventricular ejection fraction (LVEF) ≥ 50%

• Able to swallow oral medication